Cited by 502Sepsis Diagnosis and TreatmentAntibiotics Pharmacokinetics and EfficacyAcute Kidney Injury Research

The DOI matches its Crossref record; 23 of the 25 references it cites were found in a registry or an index.

Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients With Septic Shock and Elevated Endotoxin Level: The EUPHRATES Randomized Clinical Trial

Open access

Dellinger, R. Phillip, Bagshaw, Sean M., Antonelli, Massimo, Foster, Debra M., Klein, David J., Marshall, John C., Palevsky, Paul M., Weisberg, Lawrence S., Schorr, Christa A., Trzeciak, Stephen, Walker, Paul M., for the EUPHRATES Trial Investigators·2018·JAMA

DOI 10.1001/jama.2018.14618PMC PMC6233793

Open this paper in CoChat — free account Open PDF

Abstract

Importance: Polymyxin B hemoperfusion reduces blood endotoxin levels in sepsis. Endotoxin activity can be measured in blood with a rapid assay. Treating patients with septic shock and elevated endotoxin activity using polymyxin B hemoperfusion may improve clinical outcomes. Objective: To test whether adding polymyxin B hemoperfusion to conventional medical therapy improves survival compared with conventional therapy alone among patients with septic shock and high endotoxin activity. Design, Setting, and Participants: Multicenter, randomized clinical trial involving 450 adult critically ill patients with septic shock and an endotoxin activity assay level of 0.60 or higher enrolled between September 2010 and June 2016 at 55 tertiary hospitals in North America. Last follow-up was June 2017. Interventions: Two polymyxin B hemoperfusion treatments (90-120 minutes) plus standard therapy completed within 24 hours of enrollment (n = 224 patients) or sham hemoperfusion plus standard therapy (n = 226 patients). Main Outcomes and Measures: The primary outcome was mortality at 28 days among all patients randomized (all participants) and among patients randomized with a multiple organ dysfunction score (MODS) of more than 9. Results: Among 450 eligible enrolled patients (mean age, 59.8 years; 177 [39.3%] women; mean APACHE II score 29.4 [range, 0-71 with higher scores indicating greater severity), 449 (99.8%) completed the study. Polymyxin B hemoperfusion was not associated with a significant difference in mortality at 28 days among all participants (treatment group, 84 of 223 [37.7%] vs sham group 78 of 226 [34.5%]; risk difference [RD], 3.2%; 95% CI, -5.7% to 12.0%; relative risk [RR], 1.09; 95% CI, 0.85-1.39; P = .49) or in the population with a MODS of more than 9 (treatment group, 65 of 146 [44.5%] vs sham, 65 of 148 [43.9%]; RD, 0.6%; 95% CI, -10.8% to 11.9%; RR, 1.01; 95% CI, 0.78-1.31; P = .92). Overall, 264 serious adverse events were reported (65.1% treatment group vs 57.3% sham group). The most frequent serious adverse events were worsening of sepsis (10.8% treatment group vs 9.1% sham group) and worsening of septic shock (6.6% treatment group vs 7.7% sham group). Conclusions and Relevance: Among patients with septic shock and high endotoxin activity, polymyxin B hemoperfusion treatment plus conventional medical therapy compared with sham treatment plus conventional medical therapy did not reduce mortality at 28 days. Trial Registration: ClinicalTrials.gov Identifier: NCT01046669.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1001/jama.2018.14618

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock
Dellinger, R. P., Levy, M. M., Rhodes, A., Annane, D., Gerlach, H., Opal, S. M., Sevransky, J. E., Sprung, C. L., Douglas, I. S., Jaeschke, R., et al. (2013) · Critical Care Medicine · doi:10.1097/ccm.0b013e31827e83af · Cited by 9,694
Self-citation
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012
Dellinger, R. P., Levy, M. M., Rhodes, A., Annane, D., Gerlach, H., Opal, S. M., Sevransky, J., Sprung, C. L., Douglas, I. S., Jaeschke, R., et al. (2013) · Intensive Care Medicine · doi:10.1007/s00134-012-2769-8 · Cited by 7,371
Self-citation
Intravenous Fluids and Acute Kidney Injury
Ding, X., Cheng, Z., & Qian, Q. (2017) · Blood Purification · doi:10.1159/000452702 · Cited by 6,869
Early Use of Polymyxin B Hemoperfusion in Abdominal Septic Shock
Cruz, D. N., Antonelli, M. M., Fumagalli, R., Foltran, F., Brienza, N., Donati, A., Malcangi, V., Petrini, F., Volta, G., Pallavicini, F. M. B., et al. (2009) · JAMA · doi:10.1001/jama.2009.856 · Cited by 841
Self-citation
Effect of Eritoran, an Antagonist of MD2-TLR4, on Mortality in Patients With Severe Sepsis: The ACCESS Randomized Trial
Opal, S. M., Laterre, P.-F., Francois, B., LaRosa, S. P., Angus, D. C., Mira, J.-P., Wittebole, X., Dugernier, T., Perrotin, D., Tidswell, M., et al. (2013) · JAMA · doi:10.1001/jama.2013.2194 · Cited by 812
Relationship between Plasma Levels of Lipopolysaccharide (LPS) and LPS‐Binding Protein in Patients with Severe Sepsis and Septic Shock
Opal, S. M., Scannon, P. J., Vincent, J., White, M., Carroll, S. F., Palardy, J. E., Parejo, N. A., Pribble, J. P., & Lemke, J. H. (1999) · The Journal of Infectious Diseases · doi:10.1086/315093 · Cited by 609
Surviving Sepsis Campaign
Levy, M. M., Rhodes, A., Phillips, G. S., Townsend, S. R., Schorr, C., Beale, R. J., Osborn, T. M., Lemeshow, S. A., Chiche, J., Artigas, A., et al. (2014) · Critical Care Medicine · doi:10.1097/ccm.0000000000000723 · Cited by 583
Self-citation
Treatment of Septic Shock with Human Monoclonal Antibody HA-1A
McCloskey, R. V., Straube, R. C., Sanders, C., Smith, S. M., Smith, C. R., & and CHESS Trial Study Group. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-121-1-199407010-00001 · Cited by 492
Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial
The ABDOMIX Group, Payen, D. M., Guilhot, J., Launey, Y., Lukaszewicz, A. C., Kaaki, M., Veber, B., Pottecher, J., Joannès-Boyau, O., Martin‐Lefèvre, L., et al. (2015) · Intensive Care Medicine · doi:10.1007/s00134-015-3751-z · Cited by 418
Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial
Levin, M., Quint, P. A., Goldstein, B., Barton, P., Bradley, J. S., Shemie, S., Yeh, T. S., Kim, S. S., Cafaro, D. P., Scannon, P. J., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02712-4 · Cited by 408

Show all 25 references

Sorted by citations

Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021.
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000005337 · Cited by 2,935
Self-citation
Acute kidney injury from sepsis: current concepts, epidemiology, pathophysiology, prevention and treatment
Peerapornratana, S., Manrique‐Caballero, C. L., Gómez, H., & Kellum, J. A. (2019) · Kidney International · doi:10.1016/j.kint.2019.05.026 · Cited by 1,557
Sepsis associated acute kidney injury
Poston, J. T., & Koyner, J. L. (2019) · BMJ · doi:10.1136/bmj.k4891 · Cited by 917
COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup
Nadim, M. K., Forni, L. G., Mehta, R. L., Connor, M. J., Jr., Liu, K. D., Ostermann, M., Rimmele, T. R., Zarbock, A., Bell, S., Bihorac, A., et al. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-00356-5 · Cited by 701
Sepsis—Pathophysiology and Therapeutic Concepts
Jarczak, D., Kluge, S., & Nierhaus, A. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.628302 · Cited by 530
Bloodstream infections in critically ill patients: an expert statement
Timsit, J., Ruppé, É., Barbier, F., Tabah, A., & Bassetti, M. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-05950-6 · Cited by 487
Rescuing the Last-Line Polymyxins: Achievements and Challenges
Nang, S. C., Azad, M. A. K., Velkov, T., Zhou, Q. (., & Li, J. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000020 · Cited by 428
Prognostic and predictive enrichment in sepsis
Stanski, N. L., & Wong, H. R. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0199-3 · Cited by 411
Redefining critical illness
Maslove, D. M., Tang, B. M. P., Shankar‐Hari, M., Lawler, P. R., Angus, D. C., Baillie, J. K., Baron, R. M., Bauer, M. W., Buchman, T. G., Calfee, C. S., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01843-x · Cited by 373
Self-citation
Signaling pathways and intervention therapies in sepsis
Zhang, Y., & Ning, B. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00816-9 · Cited by 369
Sepsis therapies: learning from 30 years of failure of translational research to propose new leads
Cavaillon, J., Singer, M., & Skirecki, T. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201810128 · Cited by 333
The Global Burden of Sepsis and Septic Shock
Via, L. L., Sangiorgio, G., Stefani, S., Marıno, A., Nunnari, G., Cocuzza, S. G., Mantia, I. L., Cacopardo, B. S., Stracquadanio, S., Spampinato, S., et al. (2024) · Epidemiologia · doi:10.3390/epidemiologia5030032 · Cited by 313
Polymyxin B hemoperfusion in endotoxemic septic shock patients without extreme endotoxemia: a post hoc analysis of the EUPHRATES trial
Klein, D. J., Foster, D., Walker, P. M., Bagshaw, S. M., Mekonnen, H., & Antonelli, M. M. (2018) · Intensive Care Medicine · doi:10.1007/s00134-018-5463-7 · Cited by 261
Self-citation
The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2020 (J-SSCG 2020)
Egi, M., Ogura, H., Yatabe, T., Atagi, K., Inoue, S., Iba, T., Kakihana, Y., Kawasaki, T., Kushimoto, S., Kuroda, Y., et al. (2021) · Journal of Intensive Care · doi:10.1186/s40560-021-00555-7 · Cited by 232
Endotoxin and cytokine reducing properties of the oXiris membrane in patients with septic shock: A randomized crossover double-blind study
Broman, M., Hansson, F., Vincent, J., & Bodelsson, M. (2019) · PLoS ONE · doi:10.1371/journal.pone.0220444 · Cited by 211
Prescription of CRRT: a pathway to optimize therapy
Karkar, A. M., & Ronco, C. (2020) · Annals of Intensive Care · doi:10.1186/s13613-020-0648-y · Cited by 204
Cytokine removal in human septic shock: Where are we and where are we going?
Honore, P. M., Hoste, E., Molnár, Z., Jacobs, R., Joannes-Boyau, O., Malbrain, M. L. N. G., & Forni, L. G. (2019) · Annals of Intensive Care · doi:10.1186/s13613-019-0530-y · Cited by 192
Hemoperfusion: technical aspects and state of the art
Ronco, C., & Bellomo, R. (2022) · Critical Care · doi:10.1186/s13054-022-04009-w · Cited by 190
Targeting Cytokines, Pathogen-Associated Molecular Patterns, and Damage-Associated Molecular Patterns in Sepsis via Blood Purification
Moriyama, K., & Nishida, O. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168882 · Cited by 158
Which Multicenter Randomized Controlled Trials in Critical Care Medicine Have Shown Reduced Mortality? A Systematic Review
Santacruz, C. A., Pereira, A. J., Celis, É., & Vincent, J. (2019) · Critical Care Medicine · doi:10.1097/ccm.0000000000004000 · Cited by 155
Current practice and evolving concepts in septic shock resuscitation
Bakker, J., Kattan, E., Annane, D., Castro, R., Cecconi, M., Backer, D. D., Dubín, A., Evans, L., Gong, M. N., Hamzaoui, O., et al. (2021) · Intensive Care Medicine · doi:10.1007/s00134-021-06595-9 · Cited by 158
Immunotherapy in sepsis - brake or accelerate?
Steinhagen, F., Schmidt, S. V., Schewe, J., Peukert, K., Klinman, D. M., & Bode, C. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107476 · Cited by 152
Acute Kidney Injury in Sepsis
Pais, T., Jorge, S. C., & Lopes, J. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115924 · Cited by 157
Extracorporeal Blood Purification and Organ Support in the Critically Ill Patient during COVID-19 Pandemic: Expert Review and Recommendation
Ronco, C., Bagshaw, S. M., Bellomo, R., Clark, W. R., Husain‐Syed, F., Kellum, J. A., Ricci, Z., Rimmele, T. R., Reis, T. D. A., & Ostermann, M. (2020) · Blood Purification · doi:10.1159/000508125 · Cited by 131
Self-citation
PAMPs and DAMPs in Sepsis: A Review of Their Molecular Features and Potential Clinical Implications
Cicchinelli, S., Pignataro, G., Gemma, S., Piccioni, A., Picozzi, D., Ojetti, V., Franceschi, F., & Candelli, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25020962 · Cited by 128
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Intensive Care Medicine · doi:10.1007/s00134-021-06506-y · Cited by 5,082
Self-citation
S3-Leitlinie Sepsis – Prävention, Diagnose, Therapie und Nachsorge
Deutsche Sepsis Gesellschaft e., V., Brunkhorst, F. M., Weigand, M. A., Pletz, M. W., Gastmeier, P., Lemmen, S., Meier‐Hellmann, A., Ragaller, M., Weyland, A., Marx, G., et al. (2020) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-020-00685-0 · Cited by 128
Hemoperfusion in the intensive care unit
Ricci, Z., Romagnoli, S., Reis, T. D. A., Bellomo, R., & Ronco, C. (2022) · Intensive Care Medicine · doi:10.1007/s00134-022-06810-1 · Cited by 125
Heparin 2.0: A New Approach to the Infection Crisis
Seffer, M., Cottam, D., Forni, L. G., & Kielstein, J. T. (2020) · Blood Purification · doi:10.1159/000508647 · Cited by 107
Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2026
Prescott, H. C., Antonelli, M. M., Alhazzani, W. A., Møller, M. H., Alshamsi, F. E., Azevedo, L. C. P., Belley‐Côté, E. P., Waele, J. D., Derde, L. P. G., Dionne, J. C., et al. (2026) · Intensive Care Medicine · doi:10.1007/s00134-026-08361-1 · Cited by 149
Self-citation
Renal Replacement Techniques in Septic Shock
Hellman, T., Uusalo, P., & Järvisalo, M. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910238 · Cited by 111
Biomarkers of Infection and Sepsis
Opal, S. M., & Wittebole, X. (2019) · Critical Care Clinics · doi:10.1016/j.ccc.2019.08.002 · Cited by 101
Sepsis-associated acute kidney injury: recent advances in enrichment strategies, sub-phenotyping and clinical trials
Legrand, M. M., Bagshaw, S. M., Bhatraju, P. K., Bihorac, A., Caniglia, E. C., Khanna, A. K., Kellum, J. A., Koyner, J. L., Harhay, M. O., Zampieri, F. G., et al. (2024) · Critical Care · doi:10.1186/s13054-024-04877-4 · Cited by 111
Self-citation
Blood Purification and Mortality in Sepsis and Septic Shock
Putzu, A., Schorer, R., Delgado, J. C. L., Cassina, T., & Landoni, G. (2019) · Anesthesiology · doi:10.1097/aln.0000000000002820 · Cited by 96
Challenges in the management of septic shock: a narrative review
Backer, D. D., Cecconi, M., Lipman, J., Machado, F. R., Myatra, S. N., Ostermann, M., Perner, A., Teboul, J., Vincent, J., & Walley, K. R. (2019) · Intensive Care Medicine · doi:10.1007/s00134-019-05544-x · Cited by 95
The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2020 (J‐SSCG 2020)
Egi, M., Ogura, H., Yatabe, T., Atagi, K., Inoue, S., Iba, T., Kakihana, Y., Kawasaki, T., Kushimoto, S., Kuroda, Y., et al. (2021) · Acute Medicine & Surgery · doi:10.1002/ams2.659 · Cited by 88
Therapeutic plasma exchange in patients with life-threatening COVID-19: a randomised controlled clinical trial
Faqihi, F. A., Alharthy, A. M., Abdulaziz, S., Balhamar, A., Al‐Omari, A., Aseri, Z. A. A., Tamim, H., Alqahtani, S. A., Kutsogiannis, D. J., Brindley, P. G., et al. (2021) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2021.106334 · Cited by 89
Surviving Sepsis campaign: international guidelines for Management of Sepsis and Septic Shock 2026
Prescott, H. C., Antonelli, M., Alhazzani, W., Møller, M. H., Alshamsi, F., Azevedo, L. C. P., Belley-Cote, E., De Waele, J., Derde, L., Dionne, J. C., et al. (2026) · Critical Care Medicine · doi:10.1097/ccm.0000000000007075 · Cited by 117
Self-citation
Rationale for sequential extracorporeal therapy (SET) in sepsis
Ronco, C., Chawla, L. S., Husain‐Syed, F., & Kellum, J. A. (2023) · Critical Care · doi:10.1186/s13054-023-04310-2 · Cited by 89
The role of endotoxin in septic shock
Kellum, J. A., & Ronco, C. (2023) · Critical Care · doi:10.1186/s13054-023-04690-5 · Cited by 86
The therapeutic efficacy of adjunct therapeutic plasma exchange for septic shock with multiple organ failure: a single-center experience
Keith, P. D., Wells, A. H., Hodges, J., Fast, S. H., Adams, A., & Scott, L. K. (2020) · Critical Care · doi:10.1186/s13054-020-03241-6 · Cited by 83
Endotoxin in Sepsis: Methods for LPS Detection and the Use of Omics Techniques
Virzì, G. M., Mattiotti, M., de Cal, M., Ronco, C., Zanella, M., & Rosa, S. D. (2022) · Diagnostics · doi:10.3390/diagnostics13010079 · Cited by 82
Continuous renal replacement therapy with the addition of CytoSorb cartridge in critically ill patients with COVID‐19 plus acute kidney injury: A case‐series
Alharthy, A. M., Faqihi, F. A., Memish, Z. A., Balhamar, A., Nasim, N., Shahzad, A., Tamim, H., Alqahtani, S. A., Brindley, P. G., & Karakitsos, D. (2020) · Artificial Organs · doi:10.1111/aor.13864 · Cited by 80
Sepsis-induced AKI: From pathogenesis to therapeutic approaches
He, F.-F., Wang, Y., Chen, Y., Huang, W. C., Li, Z., & Zhang, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.981578 · Cited by 86
Continuous Renal Replacement Therapy with the Adsorbing Filter oXiris in Septic Patients: A Case Series
Turani, F., Barchetta, R., Falco, M., Busatti, S., & Weltert, L. P. (2019) · Blood Purification · doi:10.1159/000499589 · Cited by 80
Surviving Sepsis Campaign Guidelines 2021: highlights for the practicing clinician
Oczkowski, S. J. W., Alshamsi, F. E., Belley‐Côté, E. P., Centofanti, J., Møller, M. H., Nunnally, M., & Alhazzani, W. A. (2022) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.16290 · Cited by 85
The End of “One Size Fits All” Sepsis Therapies: Toward an Individualized Approach
Vincent, J., van der Poll, T., & Marshall, J. C. (2022) · Biomedicines · doi:10.3390/biomedicines10092260 · Cited by 85
Self-citation
Contemporary strategies to improve clinical trial design for critical care research: insights from the First Critical Care Clinical Trialists Workshop
Harhay, M. O., Casey, J. D., Clément, M., Collins, S. P., Gayat, É., Gong, M. N., Jaber, S., Laterre, P., Marshall, J. C., Matthay, M. A., et al. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-05934-6 · Cited by 79
Self-citation
Anticoagulant chitosan-kappa-carrageenan composite hydrogel sorbent for simultaneous endotoxin and bacteria cleansing in septic blood
Li, Y., Li, J., Shi, Z., Wang, Y., Song, X., Wang, L., Han, M., Du, H., He, C., Zhao, W., et al. (2020) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2020.116470 · Cited by 69
Towards personalized medicine: a scoping review of immunotherapy in sepsis
Slim, M. A., van Mourik, N., Bakkerus, L., Fuller, K., Acharya, L. S., Giannidis, T., Dionne, J. C., Oczkowski, S. J. W., Netea, M. G., Pickkers, P., et al. (2024) · Critical Care · doi:10.1186/s13054-024-04964-6 · Cited by 93
A review of gut failure as a cause and consequence of critical illness
Soranno, D. E., Coopersmith, C. M., Brinkworth, J. F., Factora, F. N., Muntean, J. H., Mythen, M. G., Raphael, J., Shaw, A., Vachharajani, V., & Messer, J. S. (2025) · Critical Care · doi:10.1186/s13054-025-05309-7 · Cited by 77
Effectiveness of polymyxin B hemoperfusion for sepsis depends on the baseline SOFA score: a nationwide observational study
Fujimori, K., Tarasawa, K., & Fushimi, K. (2021) · Annals of Intensive Care · doi:10.1186/s13613-021-00928-z · Cited by 68
Use of extracorporeal blood purification therapies in sepsis: the current paradigm, available evidence, and future perspectives
Bottari, G., Ranieri, V. M., İnce, C., Pesenti, A., Aucella, F., Scandroglio, A. M., Ronco, C., & Vincent, J. (2024) · Critical Care · doi:10.1186/s13054-024-05220-7 · Cited by 72
Blood Purification for Adult Patients With Severe Infection or Sepsis/Septic Shock: A Network Meta-Analysis of Randomized Controlled Trials
Chen, J., Lai, P.-C., Lee, T. H., & Huang, Y. (2023) · Critical Care Medicine · doi:10.1097/ccm.0000000000005991 · Cited by 68
Blood Purification Techniques for Sepsis and Septic AKI
Girardot, T., Schneider, A. G., & Rimmele, T. R. (2019) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2019.06.010 · Cited by 65
Subtypes and Mimics of Sepsis
Kellum, J. A., Formeck, C. L., Kernan, K. F., Gómez, H., & Carcillo, J. A. (2022) · Critical Care Clinics · doi:10.1016/j.ccc.2021.11.013 · Cited by 62
Extracorporeal Blood Purification and Acute Kidney Injury in Cardiac Surgery
Pérez-Fernández, X. L., Ulsamer, A., Cámara-Rosell, M. L., Sbraga, F., Boza-Hernández, E., Ruiz, E. M., Plata-Menchaca, E. P., Santiago-Bautista, D., Boronat-García, P., Gumucio-Sanguino, V. D., et al. (2024) · JAMA · doi:10.1001/jama.2024.20630 · Cited by 64
Disease Mechanisms of Perioperative Organ Injury
Conrad, C., & Eltzschig, H. K. (2020) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000005191 · Cited by 63
Endotoxic Septic Shock: Diagnosis and Treatment
Foster, D., & Kellum, J. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216185 · Cited by 63
Self-citation
Mortality and adverse events of hemoadsorption with CytoSorb ® in critically ill patients: A systematic review and meta‐analysis of randomized controlled trials
Heymann, M., Schorer, R., & Putzu, A. (2022) · Acta Anaesthesiologica Scandinavica · doi:10.1111/aas.14115 · Cited by 57
Effect of Extracorporeal Blood Purification on Mortality in Sepsis: A Meta-Analysis and Trial Sequential Analysis
Snow, T. A. C., Littlewood, S., Corredor, C., Singer, M., & Arulkumaran, N. (2020) · Blood Purification · doi:10.1159/000510982 · Cited by 55
Therapeutic plasma exchange in adult critically ill patients with life-threatening SARS-CoV-2 disease: A pilot study
Faqihi, F. A., Alharthy, A. M., Al-Odat, M. A., Kutsogiannis, D. J., Brindley, P. G., & Karakitsos, D. (2020) · Journal of Critical Care · doi:10.1016/j.jcrc.2020.07.001 · Cited by 52
Nebulized Colistin in Ventilator-Associated Pneumonia and Tracheobronchitis: Historical Background, Pharmacokinetics and Perspectives
Zhu, Y., Monsel, A., Roberts, J. A., Pontikis, K., Mimoz, O., Rello, J., Qu, J., Rouby, J., & on behalf of the European Investigator Network for Nebulized Antibiotics in Ventilator-Associated Pneumonia (ENAVAP) (2021) · Microorganisms · doi:10.3390/microorganisms9061154 · Cited by 51
The role of thromboinflammation in acute kidney injury among patients with septic coagulopathy
Iba, T., Helms, J., Maier, C. L., Levi, M. M., Scărlătescu, E., & Levy, J. H. (2024) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2024.02.006 · Cited by 53
Is Mortality a Useful Primary End Point for Critical Care Trials?
Veldhoen, R. A., Howes, D. W., & Maslove, D. M. (2019) · CHEST Journal · doi:10.1016/j.chest.2019.11.019 · Cited by 49
Extracorporeal haemoadsorption: does the evidence support its routine use in critical care?
Supady, A., Brodie, D., & Wengenmayer, T. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00451-3 · Cited by 49
Precision medicine in sepsis and septic shock: From omics to clinical tools
Ruiz‐Rodríguez, J. C., Plata-Menchaca, E. P., Chiscano‐Camón, L., Ruiz-Sanmartín, A., Pérez-Carrasco, M., Palmada, C., Ribas, V. J., Martínez‐Gallo, M., Hernández-González, M., González‐López, J. J., et al. (2022) · World Journal of Critical Care Medicine · doi:10.5492/wjccm.v11.i1.1 · Cited by 49
Extracorporeal hemoperfusion therapy for sepsis: Multi-lamellar microspheres towards cascade endotoxin removal and broad-spectrum radical eliminating
Wei, Z., Fan, Z., Peng, G., Si, H., Li, Y., Wang, Z., Yin, S., Chen, S., Wang, R., Xie, Y., et al. (2022) · Chemical Engineering Journal · doi:10.1016/j.cej.2022.136499 · Cited by 49
Extracorporeal blood purification strategies in sepsis and septic shock: An insight into recent advancements
Mehta, Y. B., Paul, R. K., Ansari, A. S., Banerjee, T., Günaydın, S., Nassiri, A. A., Pappalardo, F., Premužić, V., Sathe, P., Singh, V. K., et al. (2023) · World Journal of Critical Care Medicine · doi:10.5492/wjccm.v12.i2.71 · Cited by 48
Targeted therapy using polymyxin B hemadsorption in patients with sepsis: a post-hoc analysis of the JSEPTIC-DIC study and the EUPHRATES trial
Osawa, I., Goto, T., Kudo, D., Hayakawa, M., Yamakawa, K., Kushimoto, S., Foster, D., Kellum, J. A., & Doi, K. (2023) · Critical Care · doi:10.1186/s13054-023-04533-3 · Cited by 48
Self-citation
Continuous Renal Replacement Therapy With Adsorbing Filter oXiris in Acute Kidney Injury With Septic Shock: A Retrospective Observational Study
Guan, M., Wang, H., Tang, X., Zhao, Y., Wang, F., Zhang, L., & Fu, P. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.789623 · Cited by 50
Ultraporous Polyquaternium-Carboxylated Chitosan Composite Hydrogel Spheres with Anticoagulant, Antibacterial, and Rapid Endotoxin Removal Profiles for Sepsis Treatment
Liu, X., Xu, T., Jiang, C., Li, Y., Su, B., Zhao, W., & Zhao, C. (2022) · Biomacromolecules · doi:10.1021/acs.biomac.2c00583 · Cited by 48
RIPK1 in the inflammatory response and sepsis: Recent advances, drug discovery and beyond
Liu, X., Tang, A.-L., Chen, J., Gao, N., Zhang, G., & Xiao, C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1114103 · Cited by 48
Continuous renal replacement therapy and extended indications
Ronco, C., & Reis, T. D. A. (2021) · Seminars in Dialysis · doi:10.1111/sdi.12963 · Cited by 45
Effectiveness of polymyxin B-immobilized hemoperfusion against sepsis and septic shock: A systematic review and meta-analysis
Li, X., Liu, C., Mao, Z., Qi, S., Song, R., & Zhou, F. (2020) · Journal of Critical Care · doi:10.1016/j.jcrc.2020.09.007 · Cited by 47
A critical review of hemoperfusion adsorbents: materials, functionalization and matrix structure selection
Dou, W., Wang, J., Yao, Z., Wei, X., Huang, M., & Zhang, L. (2021) · Materials Advances · doi:10.1039/d1ma00892g · Cited by 44
The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2024
Shime, N., Nakada, T.-A., Yatabe, T., Yamakawa, K., Aoki, Y., Inoue, S., Iba, T., Ogura, H., Kawai, Y., Kawaguchi, A., et al. (2025) · Journal of Intensive Care · doi:10.1186/s40560-025-00776-0 · Cited by 45
Extracorporeal blood purification therapies for sepsis-associated acute kidney injury in critically ill patients: expert opinion from the SIAARTI-SIN joint commission
Rosa, S. D., Marengo, M., Fiorentino, M., Fanelli, V., Brienza, N., Fiaccadori, E., Grasselli, G., Morabito, S., Pota, V., Romagnoli, S., et al. (2023) · Journal of Nephrology · doi:10.1007/s40620-023-01637-5 · Cited by 41
Beneficial effects of recombinant CER-001 high-density lipoprotein infusion in sepsis: results from a bench to bedside translational research project
Stasi, A., Fiorentino, M., Franzin, R., Staffieri, F., Carparelli, S., Losapio, R., Crovace, A. M., Lacitignola, L., Cimmarusti, M. T., Murgolo, F., et al. (2023) · BMC Medicine · doi:10.1186/s12916-023-03057-5 · Cited by 40
Renal Replacement Therapy in the Critical Care Setting
Ahmed, A. R., Obilana, A., & Lappin, D. W. P. (2019) · Critical Care Research and Practice · doi:10.1155/2019/6948710 · Cited by 44
Reverse takotsubo cardiomyopathy in fulminant COVID-19 associated with cytokine release syndrome and resolution following therapeutic plasma exchange: a case-report
Faqihi, F. A., Alharthy, A. M., Alshaya, R. A., Papanikolaou, J., Kutsogiannis, D. J., Brindley, P. G., & Karakitsos, D. (2020) · BMC Cardiovascular Disorders · doi:10.1186/s12872-020-01665-0 · Cited by 41
Lung Injury in COVID-19─An Emerging Hypothesis
Alharthy, A. M., Faqihi, F. A., Memish, Z. A., & Karakitsos, D. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00422 · Cited by 38
Therapeutic Rationale for Endotoxin Removal with Polymyxin B Immobilized Fiber Column (PMX) for Septic Shock
Shoji, H., & Opal, S. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042228 · Cited by 37
The Burden of Sepsis and Septic Shock in the Intensive Care Unit
Via, L. L., Maniaci, A., Lentini, M., Cuttone, G., Ronsivalle, S., Tutino, S., Rubulotta, F. M., Nunnari, G., & Marıno, A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14196691 · Cited by 47
Blood purification for sepsis: an overview
Zhang, L., Feng, Y., & Fu, P. (2021) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbab005 · Cited by 40
Effects of Polymyxin B Hemoperfusion on Septic Shock Patients Requiring Noradrenaline: Analysis of a Nationwide Administrative Database in Japan
Fujimori, K., Tarasawa, K., & Fushimi, K. (2021) · Blood Purification · doi:10.1159/000513213 · Cited by 36
Septic shock in adults: guidelines of the All-Russian public organization “Federation of Anesthesiologists and Reanimatologists”
Кirov, М. Y., Владимирович, К. В., Николаевич, П. Д., Щеголев, А. В., Babaev, M. A., Belotserkovskiy, B. Z., Bykov, A. O., Gritsan, A. I., Кулабухов, В. В., Kulikov, A. V., et al. (2023) · Annals of critical care · doi:10.21320/1818-474x-2023-4-7-42 · Cited by 38
Chromatin-Associated Molecular Patterns (CAMPs) in sepsis
Nofi, C. P., Wang, P., & Aziz, M. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05155-3 · Cited by 35
Clinical trial design for unmet clinical needs: a spotlight on sepsis
Vincent, J., & Sakr, Y. L. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1643235 · Cited by 34
Early ICU-mortality in sepsis – causes, influencing factors and variability in clinical judgement: a retrospective cohort study
Driessen, R., Heijnen, N. F. L., Hulsewe, R. P. M. G., Holtkamp, J. W. M., Winkens, B., van der Horst, I. C. C., van der Horst, I. C. C., Bergmans, D. C. J. J., & Schnabel, R. M. (2020) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2020.1821912 · Cited by 34
Impact of critical illness on cholesterol and fatty acids: insights into pathophysiology and therapeutic targets
Lauwers, C., Bruyn, L. D., & Langouche, L. (2023) · Intensive Care Medicine Experimental · doi:10.1186/s40635-023-00570-y · Cited by 35
Polymyxin B haemoadsorption in endotoxic septic shock (Tigris): a multicentre, open-label, Bayesian, randomised, controlled, phase 3 trial
Neyra, J. A., Legrand, M. M., Tidswell, M., Al-Khafaji, A., Galphin, C. M., Rains, R., Davison, D. L., Tolwani, A., Chen, J.-T., Bender, W., et al. (2026) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(26)00047-0 · Cited by 39
Self-citation
The haemodynamic effects of oXiris haemofilter in septic shock patients requiring renal support: A single-centre experience
Lumlertgul, N., & Srisawat, N. (2020) · The International Journal of Artificial Organs · doi:10.1177/0391398820917150 · Cited by 32
Vasopressor-Sparing Strategies in Patients with Shock: A Scoping-Review and an Evidence-Based Strategy Proposition
Guinot, P., Martin, A., Berthoud, V., Voizeux, P., Bartamian, L., Santangelo, E., Bouhemad, B., & Nguyen, M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10143164 · Cited by 33
Immune Modulation in Sepsis, ARDS, and Covid-19 — The Road Traveled and the Road Ahead
Leligdowicz, A., Harhay, M. O., & Calfee, C. S. (2022) · NEJM Evidence · doi:10.1056/evidra2200118 · Cited by 35
S3-Leitlinie Sepsis – Prävention, Diagnose, Therapie und Nachsorge
Deutsche Sepsis Gesellschaft e., V., Brunkhorst, F. M., Weigand, M. A., Pletz, M. W., Gastmeier, P., Lemmen, S., Meier‐Hellmann, A., Ragaller, M., Weyland, A., Marx, G., et al. (2020) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-020-00671-6 · Cited by 31
The Rationale and Current Status of Endotoxin Adsorption in the Treatment of Septic Shock
Śmiechowicz, J. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11030619 · Cited by 31
Sepsis and the evolution of human increased sensitivity to lipopolysaccharide
Brinkworth, J. F., & Valizadegan, N. (2021) · Evolutionary Anthropology: Issues, News, and Reviews · doi:10.1002/evan.21887 · Cited by 28
Altered cholesterol homeostasis in critical illness-induced muscle weakness: effect of exogenous 3-hydroxybutyrate
Goossens, C., Weckx, R., Derde, S., Perre, S. V., Derese, I., Veldhoven, P. P. V., Ghesquière, B., den Berghe, G. V., & Langouche, L. (2021) · Critical Care · doi:10.1186/s13054-021-03688-1 · Cited by 31
Extending the ‘host response’ paradigm from sepsis to cardiogenic shock: evidence, limitations and opportunities
Buckel, M., Maclean, P., Knight, J. C., Lawler, P. R., & Proudfoot, A. G. (2023) · Critical Care · doi:10.1186/s13054-023-04752-8 · Cited by 30

Authors: Dellinger, R. P., Bagshaw, S. M., Antonelli, M., Foster, D. M., Klein, D. J., Marshall, J. C., Palevsky, P. M., Weisberg, L. S., Schorr, C. A., Trzeciak, S., Walker, P. M., & for the EUPHRATES Trial Investigators
Affiliations: Cooper University Hospital (US)
University of Alberta (CA)
Università Cattolica del Sacro Cuore (IT)
Spectral Medical Inc, Toronto, Canada
St. Michael's Hospital (CA)
University of Pittsburgh (US)
Corresponding author: Dellinger, R. Phillip
ORCID: Bagshaw, Sean M.
Antonelli, Massimo
Klein, David J.
Marshall, John C.
Palevsky, Paul M.
Weisberg, Lawrence S.
Schorr, Christa A.
Trzeciak, Stephen
Venue: JAMA
Publisher: American Medical Association (AMA)
Published: 2018-10-09
Volume: 320
Issue: 14
Pages: 1455
ISSN: 0002-9955 (ISSN-L)
0098-7484
DOI: 10.1001/jama.2018.14618
PMC: PMC6233793
OpenAlex: W2897735762
Cited by: 502
References: 25
Citations by year: 2026: 73 · 2025: 71 · 2024: 71 · 2023: 70 · 2022: 52 · 2021: 54 · 2020: 63 · 2019: 40 · 2018: 5
FWCI: 31.62
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: JAMA (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Figshare (submittedVersion)
Leicester Research Archive (University of Leicester) (submittedVersion, other-oa)
Funders: University of Nebraska Medical Center
Memorial Sloan-Kettering Cancer Center
Cleveland Clinic
University of Pittsburgh
East Carolina University
Thomas Jefferson University
Temple University
University of Alberta
Medical Center, University of Pittsburgh
Topics: Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
Keywords: polymyxin B hemoperfusion, septic shock, endotoxin activity, endotoxemia, 28-day mortality, multiple organ failure, sepsis, critically ill patients, endotoxin activity assay, survival outcomes, sepsis treatment, APACHE II score, multiple organ dysfunction score, sepsis mortality
MeSH terms: Adult, Aged, Anti-Bacterial Agents, Endotoxins, Female, Humans, Male, Middle Aged, Polymyxin B, Shock, Septic, Survival Analysis, Hospital Mortality, APACHE

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients With Septic Shock and Elevated Endotoxin Level: The EUPHRATES Randomized Clinical Trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks